异基因造血干细胞移植患者行治疗性血浆置换不良反应的影响因素分析

秦敬媛 ,  隆靖 ,  袁丽莉 ,  张月梅 ,  乔佳丽 ,  杨雪莲 ,  尹晴雪 ,  陈娟

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1254 -1261.

PDF (1406KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1254 -1261. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.09.013
论著

异基因造血干细胞移植患者行治疗性血浆置换不良反应的影响因素分析

作者信息 +

Risk factors for therapeutic plasma exchange-related adverse events in patients undergoing allogeneic hematopoietic stem cell transplantation

Author information +
文章历史 +
PDF (1439K)

摘要

目的 探讨异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)患者行治疗性血浆置换(therapeutic plasma exchange,TPE)过程中不良反应的发生情况及其独立危险因素,为临床安全实施TPE提供参考依据。方法 回顾性分析2022年3月至2023年12月于本科接受TPE治疗的167例allo-HSCT患者的临床资料,共计385次TPE治疗。根据是否发生不良反应将患者分为两组,收集其基线资料、置换参数及临床特征,采用单因素及多因素Firth Logistic回归分析筛选不良反应的独立危险因素。结果 167例allo-HSCT患者共接受385次TPE治疗,33例(19.8%)发生TPE相关不良反应。其中过敏反应最常见(18例,占54.5%),其次为血压波动(11例,33.3%)和低钙血症(4例,12.1%)。不良反应严重程度以Ⅱ级为主(23例,69.7%),无Ⅳ级(死亡)病例。单因素分析显示,不同红细胞比容(hematocrit,HCT)分级(<20%、20%~30%、>30%)组间不良反应发生率差异有统计学意义(Fisher精确检验P=0.022),经Bonferroni校正后,两两比较的显著性水平设为0.0167,任一配对比较结果均未达显著水平(校正后P>0.0167)。多因素Firth Logistic回归分析显示,HCT连续变量升高(OR=1.07,95%CI:1.01~1.13,P=0.020)及因细胞因子释放综合征(cytokine release syndrome,CRS)行TPE治疗(OR=9.21,95%CI:1.25~78.00,P=0.030)可能是TPE相关不良反应的独立危险因素。ROC曲线分析显示,HCT预测不良反应的AUC为0.67(95%CI:0.57~0.77),最佳临界值为24.5%,敏感性60.6%,特异性75.4%。按该临界值进行分组,HCT≥24.5%组患者的不良反应发生率显著高于HCT<24.5%组(37.7% vs 11.4%,P<0.001)。结论 allo-HSCT患者TPE不良反应以过敏反应为主,其风险与HCT升高及CRS行TPE治疗相关。HCT≥24.5%(AUC=0.67)具中等预警价值,但不宜作为独立决策依据,需联合其他指标综合评估,CRS相关结论待扩大样本验证。优化预充方案并加强围置换期监测,是提升安全性的关键。

Abstract

Objective To investigate the incidence and independent risk factors of adverse events (AEs) associated with therapeutic plasma exchange (TPE) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to provide evidence to support the safe use of TPE in clinical practice. Methods This retrospective study included 167 allo-HSCT recipients who underwent a total of 385 TPE procedures between March 2022 and December 2023. Patients were divided into two groups according to the occurrence of TPE-related AEs. Baseline characteristics, plasma exchange parameters, and clinical features were collected. Univariate analysis and multivariable Firth logistic regression were performed to identify independent risk factors for AEs. Results A total of 385 TPE procedures were performed in 167 allo-HSCT patients, and 33 patients (19.8%) experienced TPE-related AEs. Among the 33 patients who experienced AEs, allergic reactions were the most common (n=18, 54.5%), followed by blood pressure fluctuations (n=11, 33.3%) and hypocalcemia (n=4, 12.1%). Most AEs were classified as grade II (n=23, 69.7%), and no grade IV (fatal) events were observed. Univariate analysis demonstrated a significant difference in the incidence of AEs among different hematocrit (HCT) categories (<20%, 20%-30%, and >30%) (Fisher’s exact test, P = 0.022). Although the overall difference was statistically significant, none of the pairwise comparisons remained significant after Bonferroni correction (adjusted P>0.0167). Multivariable Firth logistic regression identified higher HCT levels, analyzed as a continuous variable (OR = 1.07, 95% CI:1.01-1.13, P= 0.020), and TPE performed for cytokine release syndrome (CRS) (OR= 9.21, 95% CI:1.25-78.00, P = 0.030) as potential independent risk factors for TPE-related AEs. Receiver operating characteristic (ROC) curve analysis showed that HCT had an AUC of 0.67 (95% CI:0.57-0.77) for predicting AEs, with an optimal cutoff value of 24.5%, a sensitivity of 60.6%, and a specificity of 75.4%. Using this cutoff, the AEs rate was significantly higher in patients with HCT≥24.5% than in those with HCT<24.5% (37.7% vs 11.4%, P<0.001). Conclusion Among allo-HSCT patients receiving TPE, allergic reactions were the predominant AEs. Higher HCT levels and TPE performed for CRS may be associated with an increased risk of AEs. HCT ≥24.5% may help identify patients requiring intensified monitoring, although its discriminatory ability is moderate (AUC = 0.67) and it should not be used as a standalone criterion for clinical decision-making. Findings regarding the CRS subgroup require validation in larger cohorts. Optimizing extracorporeal circuit priming and strengthening peri-procedural monitoring may help improve the safety of TPE.

关键词

血浆置换 / 异基因造血干细胞移植 / 不良反应 / 供者特异性抗HLA抗体 / 细胞因子释放综合征

Key words

plasmapheresis / allogeneic hematopoietic stem cell transplantation / adverse reactions / donor-specific anti-HLA antibodies / cytokine release syndrome

引用本文

引用格式 ▾
秦敬媛,隆靖,袁丽莉,张月梅,乔佳丽,杨雪莲,尹晴雪,陈娟. 异基因造血干细胞移植患者行治疗性血浆置换不良反应的影响因素分析[J]. 中国输血杂志, 2026, 39(9): 1254-1261 DOI:10.13303/j.cjbt.issn.1004-549x.2026.09.013

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

CHANG Y J, PEI X Y, HUANG X J. Haematopoietic stem-cell transplantation in China in the era of targeted therapies:current advances, challenges, and future directions[J].Lancet Haematol, 2022, 9 (12): e919-e929.

[2]

李小飞,马春娅,侯瑞琴. ABO血型不合异基因造血干细胞移植受者血型检测与血液成分输注专家共识[J].中国输血杂志,2023,36(11):971-977.

[3]

LI X F, MA C Y, HOU R Q. Expert consensus on recipient blood type test and blood component transfusion after ABOincompatibility hematopoietic stem cell plantation[J].Chin J Blood Transfusion,2023,36(11):971-977.

[4]

庄远,林洁,江颖,等. 治疗性单采过程管理与质量控制专家共识[J].临床输血与检验,2023,25(1):1-9.

[5]

ZHUANG Y, LIN J, JIANG Y, et al. Expert consensus on the management and quality control of therapeutic apheresis process[J].Clin Transfus Lab Med, 2023,25(1):1-9.

[6]

STEGMAYR B, NEWMAN E, WITT V, et al. Using the world apheresis association registry helps to improve the treatment quality of therapeutic apheresis[J].Transfus Med Hemother, 2021,48(4):234-239.

[7]

仲秀利,崔文静,许燕. 血浆置换治疗肝衰竭后发生不良反应的影响因素分析及列线图预测模型的建立[J].中国肝脏病杂志(电子版),2024,16(1):52-56.

[8]

ZHONG X L, CUI W J, XU Y. Analysis of influencing factors of adverse reactions after plasma exchange therapy for liver failure and establishment of a nomogram prediction model[J].Chin J Liver Dis (Electron Version), 2024,16(1):52-56.

[9]

吴炜,肖玉,王志敏,等. 血浆置换在神经内科自身免疫性疾病临床治疗中的不良反应分析[J].中国输血杂志,2012,25(10):1073-1076.

[10]

WU W, XIAO Y, WANG Z M, et al. Analysis of adverse reactions of plasma exchange in the clinical treatment of autoimmune diseases in neurology[J].Chin J Blood Transfusion, 2012,25(10):1073-1076.

[11]

杨鹏,闻慧琴,卫玉芝,等. 血浆置换在临床危重疾病治疗中的安全性分析[J].临床输血与检验,2018,20(3):242-245.

[12]

YANG P, WEN H Q, WEI Y Z, et al. The Safety of Therapeutic Plasmapheresis in Patients with Critical Diseases[J].Clin Transfus Lab Med, 2018,20(3):242-245.

[13]

ALAGGIO R, AMADOR C, ANAGNOSTOPOULOS I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours:lymphoid neoplasms[J].Leukemia,2022,36(7):1720-1748.

[14]

中华医学会血液学分会干细胞应用学组. HLA不合造血干细胞移植患者供者特异性抗HLA抗体检测结果临床解读中国专家共识(2025年版)[J].中华血液学杂志,2025,46(10):898-904.

[15]

Stem Cell Application Group of Hematology Branch of Chinese Medical Association. Chinese expert consensus on the clinical interpretation of donor-specific anti-HLA antibody test results in HLA-mismatched hematopoietic stem cell transplantation (2025)[J].Chin J Hematol, 2025,46(10):898-904.

[16]

CONNELLY-SMITH L, ALQUIST C R, AQUI N A, et al. Guidelines on the use of therapeutic apheresis in clinical practice -evidence-based approach from the writing committee of the American Society for Apheresis:the ninth special issue[J].J Clin Apher,2023,38(2):77-278.

[17]

CARDONA V, ANSOTEGUI I J, EBISAWA M, et al. World allergy organization anaphylaxis guidance 2020[J].World Allergy Organ J,2020,13(10):100472.

[18]

COIRIER V, LESOUHAITIER M, REIZINE F, et al. Tolerance and complications of therapeutic plasma exchange by centrifugation:A single center experience[J].J Clin Apher,2022,37(1):54-64.

[19]

李玲玲,朱晓君,林洁,等. 治疗性血浆置换发生过敏反应的危险因素分析-基于单中心的研究[J].中国输血杂志,2024,37(7):748-753.

[20]

LI L L, ZHU X J, LIN J, et al. Risk factors of allergic reactions caused by therapeutic plasma exchange:a single-center analysis[J].Chin J Blood Transfusion Jul, 2024,37(7):748-753.

[21]

张鑫,王爽,邓昆. 输血不良反应的临床特点和影响因素分析[J]. 中国实验血液学杂志,2026,34(1):225-231.

[22]

ZHANG X, WANG S, DENG K. Clinical characteristics and influencing factors of adverse transfusion reactions[J].J Exp Hematol, 2026,34(1):225-231.

[23]

ABE T, AOYAMA T, TAKEUCHI Y. Evaluating risk factors for developing allergic reactions during plasma exchange using fresh-frozen plasma:A single-center retrospective study[J].Intern Med,2023,62 (19):2803-2811.

[24]

朱鸿燕,周莉,阳梅. 异基因造血干细胞移植治疗恶性血液病患者血清免疫球蛋白的动态变化及与移植物抗宿主病发生的关系[J].实用医院临床杂志,2022,19(4):162-165.

[25]

ZHU H Y, ZHOU L, YANG M. Dynamic changes of serum immunoglobulins in patients with hematological malignancy treated with allogeneic hematopoietic stem cell transplantation and their relationship with the occurrence of graft-versus-host disease[J]. Pract J Clin Med, 2022,19(4):162-165.

[26]

李佳,杨军,蒋惠,等. 外周血中性粒细胞-淋巴细胞比值、超敏C反应蛋白与输血不良反应的相关性[J].中国实验血液学杂志,2026,34(3):840-845.

[27]

LI J, YANG J, JIANG H, et al. Correlation between peripheral blood neutrophil-lymphocyte ratio, high-sensitivity C-reactive protein and adverse transfusion reactions[J].J Exp Hematol, 2026,34(3):840-845.

[28]

ZHANG J, XIE D, TANG M, et al. Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights[J].Front Immunol,2025,16:1597512.

[29]

HAY K A, HANAFI L A, LI D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy[J].Blood,2017,130(21):2295-2306.

[30]

NEELAPU S S, TUMMALA S, KEBRIAEI P, et al. Chimeric antigen receptor T-cell therapy -assessment and management of toxicities[J].Nat Rev Clin Oncol, 2018,15(1):47-62.

[31]

LI J, ZHANG Z L, ZHAO J, et al. A simple predictor for donor-specific anti-HLA antibody desensitisation in haploidentical haematopoietic stem cell transplantation[J].HLA,2024,104(2):e15625.

[32]

MCLEOD B C, SZCZEPIORKOWSKI Z M, WEINSTEIN R, et al. Apheresis:principles and practice[M]. 3rd ed. Bethesda,MD:AABB Press,2010.

[33]

REN S, HUANG L, LI Y, et al. Comparison of efficacy and safety of different anticoagulation regimens in plasma exchange: asystematic review and meta-analysis[J]. PLoS One,2024,19(10):e0311603.

AI Summary AI Mindmap
PDF (1406KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉